Pirfekast-400

Product Name Pirfekast-400
CompositionPirefenidone Tablets 400 mg
FormTablets
Manufactured ByAprazer Healthcare
PrescriptionRequired
StorageStore below 30°C

Description

Pirfekast-400

Composition- Pirefenidone Tablets

Classification- Respiratory Medicine

What is Pirfekast 400 (Pirefenidone) Tablet?

Pirfekast 400 is a pirefenidone tablet, manufactured by Aprazer Healthcare.
It reduces scarring of the lung tissues.
Pirfekast 400 (pirefenidone) tablet is used in idiopathic pulmonary fibrosis (IPF).

Where is Pirfekast 400 (Pirefenidone) Tablet Used?

It is an anti-fibrotic medicine. It is widely used to treat Pulmonary Fibrosis (IPF).
It delays the progression of the disease.
It is being investigated for use in liver fibrosis or cardiac fibrosis.

Why Choose Pirfekast 400 (Pirefenidone) Tablet by Aprazer Healthcare?

Aprazer Healthcare is the top drug manufacturer.
It specializes in manufacturing rare disease medicines.
With the largest manufacturing capacities, Aprazer Healthcare is capable of manufacturing bulk medicines to meet the existing healthcare demands.
Aprazer Healthcare is the largest pharmaceutical exporter, exporting life-saving medicines worldwide.
Globally recognized as the leading pharmaceutical manufacturer, Aprazer Healthcare’s products are the preferred choice in the top hospitals, clinics, and government hospitals.

Working of Pirfekast 400 (Pirefenidone) Tablet

It is anti-inflammatory. It inhibits inflammatory and fibrotic proteins.
It suppresses fibroblasts. It prevents the progression of scarring in the lungs.
It reduces inflammation. It helps preserve the healthy cells.

What Are the Pirfekast 400 (Pirefenidone) Tablet Side Effects?

It causes mild side effects, which often reduce over time.

• Nausea
• Vomiting
• Skin rashes
• Fatigue
• Headache
• Dizziness
• Respiratory infection
• Sinusitis

What Are the Pirfekast 400 (Pirefenidone) Tablet Severe Side Effects?

It increases the sensitivity to the sun.
It can cause sunburn, skin rashes.

It can cause a severe skin reaction-

• Blistering
• Peeling
• Mouth ulcers

An allergic reaction to the drug.

• It causes swelling of the face.
• Difficulty in breathing

It can elevate liver enzymes. It causes severe liver damage.
It causes yellowing of the skin.

• Jaundice
• Bleeding
• Bruising

What Are the Precautions for Pirfekast 400 (Pirefenidone) Tablet?

Avoid smoking with Pirfekast 400 (pirefenidone) tablet.
It can reduce its efficacy.
Do not move in the sun.
It causes a skin reaction.

Use it cautiously in people with –

• Severe liver diseases
• Kidney disorders

When Not to Use Pirfekast 400 (Pirefenidone)?

It should be used under prescription.
One must avoid smoking while using Pirfekast 400 (Pirefenidone) tablet.

It must be avoided in –

• Severe liver impairment
• Severe kidney impairment
• Allergy to the drug
• Angioedema
• Pregnancy
• Breastfeeding

What to Avoid With Pirfekast 400 (Pirefenidone) Tablet?

It shows severe drug reactions. It can lead to toxicity or under efficacy.

It should be avoided with-

• Antidepressants
• Heart medicines
• Antibiotics
• Anticonvulsants
• Anti-tubercular drugs

Conclusion

Pirfekast 400 (pirefenidone tablets) is globally available.
It is used for the treatment of lung scarring.

It offers many advantages-

• It delays disease progression.
• It preserves lung functions.
• It slows down lung scarring.

Gandhi Medicos – The Top Respiratory Medicine Distributor

Gandhi Medicos is the preferred global drug distributor for all types of life pharmaceutical drugs.
We are the top drug suppliers to the leading hospitals and clinics.
We outsource the global standard drugs from the leading pharmaceutical manufacturers.
We offer top pharmaceutical brands. We are the trusted online pharmaceutical suppliers.
As the top respiratory medicine distributor, we export the global quality medicines worldwide.

• Assured quality and authenticity
• Affordable range
• Worldwide shipment
• Timely delivery

Reviews

There are no reviews yet.

Be the first to review “Pirfekast-400”

Your email address will not be published. Required fields are marked *